Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.
Ogbogu PU, Roufosse F, Akuthota P, Kuna P, Groh M, Reiter A, Yokota A, Siddiqui SH, Mutsaers PGNJ, Li B, Khoury P, Bahadori LM, Bednarczyk A, Bouma G, Brooks LG, Ferreira J, Grindebacke H, Ho CN, Jain P, Palmer RL, Jison ML, Klion AD; NATRON study group.
Ogbogu PU, et al.
Nat Med. 2026 Jun;32(6):2017-2025. doi: 10.1038/s41591-026-04315-8. Epub 2026 Mar 31.
Nat Med. 2026.
PMID: 41917160
Free PMC article.
Clinical Trial.